| ［1］ |
Hill MK, Kheirandish Pishkenari A, Braunberger TL, et al. Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: a systematic review［J］. J Am Acad Dermatol, 2016,75（5）:906⁃917. doi: 10.1016/j.jaad.2016. 07.002.
|
| ［2］ |
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis［J］. Dermatology, 1993,186（1）:23⁃31. doi: 10.1159/000247298.
|
| ［3］ |
Tofte S. Eczema area and severity index （EASI）: a new tool to evaluate atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 1998,11（Suppl 2）:S197. doi: 10.1016/S0926⁃9959（98）95291⁃6.
|
| ［4］ |
Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality⁃of⁃life instruments 1985⁃2010［J/OL］. PLoS One, 2011,6（4）:e17520. doi: 10.1371/journal.pone.0017520.
|
| ［5］ |
Spuls PI, Gerbens L, Simpson E, et al. Patient⁃oriented eczema measure （POEM）, a core instrument to measure symptoms in clinical trials: a harmonising outcome measures for eczema （HOME） statement［J］. Br J Dermatol, 2017,176（4）:979⁃984. doi: 10.1111/bjd.15179.
|
| ［6］ |
Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient⁃perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool （ADCT）［J］. Curr Med Res Opin, 2020,36（3）:367⁃376. doi: 10.1080/03007995. 2019.1699516.
|
| ［7］ |
Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate⁃to⁃severe atopic dermatitis［J］. Br J Dermatol, 2019,181（4）:761⁃769. doi: 10. 1111/bjd.17744.
|
| ［8］ |
Finlay AY, Khan GK. Dermatology life quality index （DLQI）⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x.
|
| ［9］ |
Lewis⁃Jones MS, Finlay AY. The Children′s Dermatology Life Quality Index （CDLQI）: initial validation and practical use［J］. Br J Dermatol, 1995,132（6）:942⁃949. doi: 10.1111/j.1365⁃2133. 1995.tb16953.x.
|
| ［10］ |
Zigmond AS, Snaith RP. The hospital anxiety and depression scale［J］. Acta Psychiatr Scand, 1983,67（6）:361⁃370.
|
| ［11］ |
Rabin R, de Charro F. EQ⁃5D: a measure of health status from the EuroQol Group［J］. Ann Med, 2001,33（5）:337⁃343. doi: 10. 3109/07853890109002087.
|
| ［12］ |
Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool （ADCT©） using a longitudinal survey of biologic⁃treated patients with atopic dermatitis［J］. BMC Dermatol, 2019,19（1）:15. doi: 10.1186/s12895⁃019⁃0095⁃3.
|
| ［13］ |
Thomas KS, Apfelbacher CA, Chalmers JR, et al. Recommended core outcome instruments for health⁃related quality of life, long⁃term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting［J］. Br J Dermatol, 2020. doi: 10.1111/bjd.19673.
|
| ［14］ |
Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis （AD）: insights from a phase 2b clinical trial of dupilumab in adults［J］. J Am Acad Dermatol, 2016,74（3）:491⁃498. doi: 10.1016/j.jaad.2015.10.043.
|
| ［15］ |
Sandhu JK, Wu KK, Bui TL, et al. Association between atopic dermatitis and suicidality: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2019,155（2）:178⁃187. doi: 10. 1001/jamadermatol.2018.4566.
|
| ［16］ |
Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systematic review and meta⁃analysis［J］. Curr Opin Allergy Clin Immunol, 2015,15（5）:453⁃460. doi: 10.1097/ACI. 0000000000000198.
|
| ［17］ |
Himadri, George R, Mathew L, et al. The role of thymus and activation⁃regulated chemokine as a marker of severity of atopic dermatitis［J］. J Am Acad Dermatol, 2021,84（2）:545⁃547. doi: 10.1016/j.jaad.2020.05.052.
|
| ［18］ |
Gu CY, Gu L, Dou X. Serum levels of thymus and activation⁃regulated chemokine can be used in the clinical evaluation of atopic dermatitis［J］. Int J Dermatol, 2015,54（7）:e261⁃e265. doi: 10.1111/ijd.12830.
|
